

Manuela Ferracin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3159397/publications.pdf>

Version: 2024-02-01

204
papers

32,239
citations

23567

58
h-index

4548

171
g-index

213
all docs

213
docs citations

213
times ranked

32784
citing authors

#	ARTICLE	IF	CITATIONS
1	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2257-2261.	7.1	5,220
2	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.9	3,719
3	<i>miR-15</i> and <i>miR-16</i> induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13944-13949.	7.1	3,287
4	A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 353, 1793-1801.	27.0	2,255
5	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11755-11760.	7.1	1,238
6	Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 2005, 334, 1351-1358.	2.1	1,009
7	A MicroRNA Signature of Hypoxia. Molecular and Cellular Biology, 2007, 27, 1859-1867.	2.3	990
8	An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9740-9744.	7.1	906
9	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer Research, 2007, 67, 6092-6099.	0.9	782
10	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	7.1	741
11	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	16.8	681
12	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27, 5651-5661.	5.9	619
13	Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 387-392.	1.6	566
14	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
15	MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer, 2006, 13, 497-508.	3.1	463
16	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 2009, 69, 5761-5767.	0.9	380
17	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 2007, 26, 7590-7595.	5.9	373
18	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306

#	ARTICLE	IF	CITATIONS
19	MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. <i>Clinical Cancer Research</i> , 2009, 15, 5073-5081.	7.0	298
20	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. <i>PLoS ONE</i> , 2009, 4, e7405.	2.5	273
21	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. <i>Cancer Research</i> , 2010, 70, 3140-3149.	0.9	272
22	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	30.7	251
23	Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. <i>Carcinogenesis</i> , 2010, 31, 1561-1566.	2.8	241
24	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. <i>Molecular Cancer</i> , 2007, 6, 54.	19.2	240
25	Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. <i>Experimental Hematology</i> , 2008, 36, 1035-1046.	0.4	240
26	Micromarkers: miRNAs in cancer diagnosis and prognosis. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 297-308.	3.1	237
27	MicroRNAs in human cancer: from research to therapy. <i>Journal of Cell Science</i> , 2007, 120, 1833-1840.	2.0	222
28	Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas. <i>Journal of Cellular Physiology</i> , 2007, 210, 370-377.	4.1	203
29	Altered miRNA expression in T regulatory cells in course of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2010, 226, 165-171.	2.3	188
30	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 3872-3879.	1.4	179
31	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033.	7.3	150
32	The P2X7 receptor is a key modulator of the PI3K/GSK3 β /VEGF signaling network: evidence in experimental neuroblastoma. <i>Oncogene</i> , 2015, 34, 5240-5251.	5.9	149
33	Regulation of microRNA Expression: the Hypoxic Component. <i>Cell Cycle</i> , 2007, 6, 1425-1430.	2.6	132
34	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy. <i>Journal of Pathology</i> , 2012, 226, 796-805.	4.5	128
35	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 2891-2904.	7.0	122
36	Familial Cancer Associated with a Polymorphism in <i>ARLTS1</i> . <i>New England Journal of Medicine</i> , 2005, 352, 1667-1676.	27.0	119

#	ARTICLE	IF	CITATIONS
37	MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in SÅ©zary syndrome. Cell Death and Disease, 2011, 2, e151-e151.	6.3	119
38	MicroRNA profiling for the identification of cancers with unknown primary tissueâ€ofâ€origin. Journal of Pathology, 2011, 225, 43-53.	4.5	117
39	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	2.5	113
40	MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Molecular Cancer, 2010, 9, 123.	19.2	107
41	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	6.4	105
42	Small extracellular vesicles deliver miRâ€21 and miRâ€217 as proâ€senescence effectors to endothelial cells. Journal of Extracellular Vesicles, 2020, 9, 1725285.	12.2	104
43	Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget, 2015, 6, 14545-14555.	1.8	103
44	MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy â€“ comparison with human epileptic samples. Scientific Reports, 2015, 5, 14143.	3.3	101
45	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	11.2	99
46	Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mechanisms of Ageing and Development, 2021, 193, 111413.	4.6	89
47	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma. PLoS ONE, 2013, 8, e56824.	2.5	80
48	Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomarker Research, 2015, 3, 12.	6.8	80
49	Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2638-2642.	2.5	78
50	MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2011, 6, 844-851.	1.1	77
51	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology, 2020, 159, 2146-2162.e33.	1.3	75
52	miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death and Disease, 2015, 6, e1823-e1823.	6.3	74
53	miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Molecular Cancer, 2013, 12, 130.	19.2	73
54	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters, 2017, 388, 320-327.	7.2	73

#	ARTICLE	IF	CITATIONS
55	Basal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2020, 21, 5572.	4.1	73
56	MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget, 2015, 6, 38695-38704.	1.8	67
57	Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. Cell Reports, 2019, 28, 104-118.e8.	6.4	67
58	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NF κ B pathway. Molecular Cancer, 2013, 12, 173.	19.2	66
59	Alzheimer's disease gene signature says: beware of brain viral infections. Immunity and Ageing, 2010, 7, 16.	4.2	65
60	Clinical Monoclonal B Lymphocytosis versus Rai O Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
61	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. Molecular Medicine, 2013, 19, 99-108.	4.4	58
62	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	5.5	58
63	Mesenchymal Progenitors Aging Highlights a miR-196 Switch Targeting HOXB7 as Master Regulator of Proliferation and Osteogenesis. Stem Cells, 2015, 33, 939-950.	3.2	56
64	MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radical Biology and Medicine, 2009, 46, 282-288.	2.9	55
65	Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers. Oncotarget, 2016, 7, 82700-82711.	1.8	54
66	microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters. Clinical Cancer Research, 2014, 20, 4141-4153.	7.0	52
67	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	7.2	52
68	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. Scientific Reports, 2019, 9, 12174.	3.3	52
69	STAT3-mediated activation of microRNA cluster 17 \hat{A} 92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica, 2014, 99, 116-124.	3.5	50
70	Gene Expression Changes in Progression of Cervical Neoplasia Revealed by Microarray Analysis of Cervical Neoplastic Keratinocytes. Journal of Cellular Physiology, 2015, 230, 806-812.	4.1	49
71	Mutated β -catenin evades a microRNA-dependent regulatory loop. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4840-4845.	7.1	48
72	The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. Journal of Pathology, 2008, 214, 594-602.	4.5	47

#	ARTICLE	IF	CITATIONS
73	MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i>/<i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research, 2020, 80, 1720-1734.	0.9	47
74	LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget, 2018, 9, 35085-35099.	1.8	46
75	Over-expression of the <i>miR-483-3p</i> overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7, 31361-31371.	1.8	45
76	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nature Communications, 2020, 11, 604.	12.8	44
77	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	2.5	44
78	Cellular and Kaposi's sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death and Disease, 2014, 5, e1559-e1559.	6.3	43
79	miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Frontiers in Genetics, 2013, 4, 64.	2.3	42
80	Estrogen Receptors and Melanoma: A Review. Cells, 2019, 8, 1463.	4.1	41
81	A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget, 2013, 4, 2271-2287.	1.8	41
82	Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNaseH2 in cells from centenarians. Cell Death and Differentiation, 2019, 26, 1845-1858.	11.2	37
83	Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology, 2009, 35, 393-400.	3.3	37
84	Peripheral Inflammatory Markers and Antioxidant Response during the Post-Acute and Chronic Phase after Severe Traumatic Brain Injury. Frontiers in Neurology, 2016, 7, 189.	2.4	36
85	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	12.8	36
86	Identification of miRNAs Differentially Expressed in Human Epilepsy with or without Granule Cell Pathology. PLoS ONE, 2014, 9, e105521.	2.5	36
87	miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. Oncotarget, 2016, 7, 28195-28206.	1.8	34
88	The extensive role of miR-155 in malignant and non-malignant diseases. Molecular Aspects of Medicine, 2019, 70, 33-56.	6.4	33
89	Peripheral leukocyte expression of the potential biomarker proteins Bdnf, Sirt1, and Psen1 is not regulated by promoter methylation in Alzheimer's disease patients. Neuroscience Letters, 2015, 605, 44-48.	2.1	32
90	Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2015, 15, 1369-1381.	3.1	31

#	ARTICLE	IF	CITATIONS
91	P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. <i>Cell Death and Disease</i> , 2021, 12, 1088.	6.3	31
92	Altered expression of selected microRNAs in melanoma: Antiproliferative and proapoptotic activity of miRNA-155. <i>International Journal of Oncology</i> , 2009, , .	3.3	30
93	MicroRNAs: Toward the Clinic for Breast Cancer Patients. <i>Seminars in Oncology</i> , 2011, 38, 764-775.	2.2	30
94	The 21st century epidemic: infections as inductors of neuro-degeneration associated with Alzheimer's Disease. <i>Immunity and Ageing</i> , 2014, 11, 22.	4.2	30
95	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. <i>Epigenomics</i> , 2019, 11, 587-604.	2.1	29
96	Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. <i>Molecular Oncology</i> , 2019, 13, 74-98.	4.6	29
97	Increase of microRNA-210, Decrease of Raptor Gene Expression and Alteration of Mammalian Target of Rapamycin Regulated Proteins following Mithramycin Treatment of Human Erythroid Cells. <i>PLoS ONE</i> , 2015, 10, e0121567.	2.5	28
98	Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4. <i>BMC Research Notes</i> , 2010, 3, 24.	1.4	27
99	Circulating Non-coding RNA as Biomarkers in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 937, 171-181.	1.6	26
100	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	3.2	25
101	OncomiR detection in circulating body fluids: a PDMS microdevice perspective. <i>Lab on A Chip</i> , 2014, 14, 4067-4075.	6.0	24
102	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. <i>Cancers</i> , 2021, 13, 451.	3.7	24
103	Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 113-121.	0.8	24
104	TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1121-1130.	3.0	23
105	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3150-3158.	1.3	23
106	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. <i>Epigenomics</i> , 2016, 8, 1347-1366.	2.1	23
107	Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation. <i>Cell Death and Disease</i> , 2019, 10, 471.	6.3	23
108	The Clinical Utility of miR-21 and let-7 in Non-small Cell Lung Cancer (NSCLC). A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 516850.	2.8	23

#	ARTICLE	IF	CITATIONS
109	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. <i>Clinical Epigenetics</i> , 2015, 7, 129.	4.1	22
110	Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer cell types. <i>Glycobiology</i> , 2019, 29, 684-695.	2.5	22
111	Persistent infections, immune-senescence and Alzheimer's disease. <i>Oncoscience</i> , 2016, 3, 135-142.	2.2	22
112	Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1547.	4.1	21
113	Quantification of Circulating MicroRNAs by Droplet Digital PCR. <i>Methods in Molecular Biology</i> , 2018, 1768, 445-457.	0.9	21
114	Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. <i>Journal of Cellular Physiology</i> , 2016, 231, 2700-2710.	4.1	20
115	Heterotopic auxiliary segment 2â€³ liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases. <i>Surgery</i> , 2018, 164, 601-603.	1.9	20
116	Monocyte chemoattractant protein-1 promoter polymorphism and plasma levels in Alzheimer's disease. <i>Immunity and Ageing</i> , 2013, 10, 6.	4.2	18
117	BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. <i>American Journal of Clinical Pathology</i> , 2020, 153, 664-671.	0.7	18
118	Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the endothelium of ApoE-deficient mice. <i>Journal of Physiology and Pharmacology</i> , 2018, 69, 35-52.	1.1	18
119	A transcriptome-wide approach reveals the key contribution of NFI-A in promoting erythroid differentiation of human CD34+ progenitors and CML cells. <i>Leukemia</i> , 2010, 24, 1220-1223.	7.2	17
120	Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children. <i>Thrombosis and Haemostasis</i> , 2020, 120, 107-120.	3.4	16
121	Tumor Suppressor Functions of <i>ARLTS1</i> in Lung Cancers. <i>Cancer Research</i> , 2007, 67, 7738-7745.	0.9	15
122	Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38âˆ’ compartment. <i>Leukemia Research</i> , 2010, 34, 1287-1295.	0.8	15
123	Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR. <i>Frontiers in Oncology</i> , 2018, 8, 447.	2.8	15
124	Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2260-2267.	0.7	15
125	Activation of Endogenous Retrovirus, Brain Infections and Environmental Insults in Neurodegeneration and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7263.	4.1	15
126	Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. <i>Mechanisms of Ageing and Development</i> , 2022, 202, 111636.	4.6	15

#	ARTICLE	IF	CITATIONS
127	MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 239-250.	5.1	14
128	Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs. <i>Scientific Reports</i> , 2020, 10, 21782.	3.3	14
129	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. <i>Molecular Oncology</i> , 2021, 15, 2732-2751.	4.6	14
130	An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2015, 113, 655-663.	3.4	13
131	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1126.	4.1	13
132	High Expression of the Sda Synthase B4GALNT2 Associates with Good Prognosis and Attenuates Stemness in Colon Cancer. <i>Cells</i> , 2020, 9, 948.	4.1	13
133	Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis. <i>Cell Death and Disease</i> , 2021, 12, 473.	6.3	13
134	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666156.	3.7	12
135	Non-coding RNA dysregulation in skin cancers. <i>Essays in Biochemistry</i> , 2021, 65, 641-655.	4.7	12
136	Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 305-318.	3.1	12
137	Altered glycosylation profile of purified plasma ACT from Alzheimer's disease. <i>Immunity and Ageing</i> , 2010, 7, S6.	4.2	11
138	Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 245-249.	3.0	11
139	Is autopsy tissue a valid control for epilepsy surgery tissue in microRNA studies?. <i>Epilepsia Open</i> , 2017, 2, 90-95.	2.4	11
140	The Sda Synthase B4GALNT2 Reduces Malignancy and Stemness in Colon Cancer Cell Lines Independently of Sialyl Lewis X Inhibition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6558.	4.1	11
141	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. <i>Biomedicines</i> , 2021, 9, 813.	3.2	11
142	MicroRNAs as biomarker of Parkinson disease?. <i>Neurology</i> , 2015, 84, 636-638.	1.1	10
143	Essential role of MED1 in the transcriptional regulation of ER-dependent oncogenic miRNAs in breast cancer. <i>Scientific Reports</i> , 2018, 8, 11805.	3.3	10
144	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. <i>Oncotarget</i> , 2014, 5, 140-149.	1.8	10

#	ARTICLE	IF	CITATIONS
145	microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review. <i>Life</i> , 2022, 12, 288.	2.4	10
146	Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	9
147	The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 113.	8.6	9
148	Involvement of the Inconstant Bursa of the Fifth Metatarsophalangeal Joint in Psoriatic Arthritis: A Clinical and Ultrasonographic Study. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	6
149	MicroRNA Isoforms Contribution to Melanoma Pathogenesis. <i>Non-coding RNA</i> , 2021, 7, 63.	2.6	6
150	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 4680.	3.7	6
151	Circulating miR-184 is a potential predictive biomarker of cardiac damage in Andersonâ€“Fabry disease. <i>Cell Death and Disease</i> , 2021, 12, 1150.	6.3	6
152	Haplotype of Single Nucleotide Polymorphisms in Exon 6 of the MZF-1 Gene and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 439-447.	2.6	5
153	Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study. <i>Journal of Hematology and Oncology</i> , 2019, 12, 114.	17.0	5
154	Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis. <i>PLoS ONE</i> , 2022, 17, e0261464.	2.5	4
155	The Non-Coding RNA Journal Club: Highlights on Recent Papers. <i>Non-coding RNA</i> , 2015, 1, 87-93.	2.6	3
156	In hepatocellular carcinoma miR-494 up-regulates the AKT/mTOR pathway and is involved in Sorafenib resistance. <i>Digestive and Liver Disease</i> , 2016, 48, e28.	0.9	3
157	Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells. <i>Cancer Research</i> , 2015, 75, 142-142.	0.9	3
158	Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 599-605.	0.2	3
159	Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes. <i>Thrombosis Research</i> , 2020, 191, 113-124.	1.7	3
160	MicroRNA Expression Profiling and Its Clinical Impact in Breast Cancer. , 2014, , 355-367.		2
161	The Non-Coding RNA Journal Club: Highlights on Recent Papersâ€“7. <i>Non-coding RNA</i> , 2019, 5, 40.	2.6	2
162	Method for the Detection of the Cleaved Form of Shiga Toxin 2a Added to Normal Human Serum. <i>Toxins</i> , 2021, 13, 94.	3.4	2

#	ARTICLE	IF	CITATIONS
163	Abstract 4785: miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. , 2014, , .		2
164	Principles of MicroRNA Involvement in Breast Cancer. Breast Diseases, 2011, 22, 238-243.	0.0	1
165	The Role of Micro-RNAs in Rheumatic Diseases: An Update. , 0, , .		1
166	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC. Annals of Oncology, 2019, 30, ii55-ii56.	1.2	1
167	MicroRNA profiling of blastic plasmacytoid dendritic cell neoplasm and myeloid sarcoma. Hematological Oncology, 2020, 38, 831-833.	1.7	1
168	Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone. Endocrine, 2021, 73, 177-185.	2.3	1
169	The Non-Coding RNA Journal Club: Highlights on Recent Papersâ€”9. Non-coding RNA, 2021, 7, 58.	2.6	1
170	Abstract 3313: Epigenetic biomarkers of prognosis in stage IIA colon cancer. Cancer Research, 2018, 78, 3313-3313.	0.9	1
171	MicroRNA-221 targets BMF and correlates with tumor multifocality in human hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A2.	0.9	0
172	240 MICRORNA-221 TARGETS BMF AND CORRELATES WITH TUMOR MULTIFOCALITY IN HUMAN HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2009, 50, S97.	3.7	0
173	Correction: Online Publication Dates for <i>Cancer Research</i> April 15, 2010 Articles. Cancer Research, 2010, 70, 4785-4786.	0.9	0
174	SectionÂ2: Spondyloarthritis. Clinical Drug Investigation, 2013, 33, 95-112.	2.2	0
175	AB0006â€¦Microna expression profiles in peripheral blood mononuclear cells of early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, A787.3-A787.	0.9	0
176	573: Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia â” implications on constitutive activation of NF-ÎºB pathway. European Journal of Cancer, 2014, 50, S138.	2.8	0
177	Age related miRNA signature in mesenchymal progenitors reveals key players in cellular performance and fate. Cytotherapy, 2015, 17, S7.	0.7	0
178	Integration of gene expression and miRNAs reveals amino acid metabolism as key metabolic hub of adaptation to long term oestrogen deprivation in ER+ breast cancer cells. European Journal of Cancer, 2016, 61, S45.	2.8	0
179	Prognostic but not predictive: focus on stage II right-sided colorectal cancer tumors. Annals of Oncology, 2017, 28, iii101.	1.2	0
180	Radically resected stage III colorectal cancer: sidedness and prognosis. Annals of Oncology, 2017, 28, vi11.	1.2	0

#	ARTICLE	IF	CITATIONS
181	Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival. <i>Annals of Oncology</i> , 2017, 28, vi14.	1.2	0
182	Circulating microRNA-23b-3p and tissue microRNA-193a-3p as promising molecular biomarkers in human hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2021, 53, S38.	0.9	0
183	MicroRNA Function in Human Hematopoiesis: Identification of Lineage- and Stage-Specific Expression Profiles, Pivotal Targets and Regulatory Circuitries.. <i>Blood</i> , 2006, 108, 1197-1197.	1.4	0
184	Significance of Aberrant Expression of MicroRNAs in Cancer Cells. , 2009, , 1-12.		0
185	Abstract 2087: miR-483-3p is an oncogene involved in nephroblastoma and in adult tumors with activated β -catenin. , 2010, , .		0
186	Abstract 2161: Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders. , 2010, , .		0
187	MicroRNAs in Cancer (An Overview). , 2011, , 1-71.		0
188	Abstract 167: Identification of miR-34a as a prognostic biomarker of Ewing sarcoma family of tumors. , 2011, , .		0
189	Abstract 150: Regulation of TGF β receptor by miR21 in Sezary syndrome. , 2011, , .		0
190	MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFR α kinase genotype.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10056-10056.	1.6	0
191	THU0468â€¦Up-Regulation of Mir-21 in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis: Changes from Baseline after Appropriate Therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 345.1-345.	0.9	0
192	Abstract 2219: STAT3 network dissection in ALK positive Anaplastic Large Cell Lymphomas. , 2014, , .		0
193	Abstract 3964: How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer. , 2015, , .		0
194	Abstract 2079: Collection of patient-derived xenografts (PDX) to study the biology and therapy of bone sarcomas. , 2018, , .		0
195	Abstract 3549: Exosome-mediated transfer of sh-CD99 is sufficient to modulate cell differentiation in Ewing sarcoma. , 2018, , .		0
196	Comparison of whole-genome expression analysis in patients with secondary adrenal insufficiency treated with conventional treatment versus modified-release hydrocortisone. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
197	Abstract 1805: Integrative analysis of microRNAs in blastic plasmacytoid dendritic cell neoplasm. , 2019, , .		0
198	Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract 5361: Isolation and genetic characterization of circulating tumor cells from cancer of unknown primary. , 2020, , .		0
200	Abstract 1417: Development of a miRNA-based prediction tool to discriminate cutaneous blastic plasmacytoid dendritic cell neoplasm from cutaneous myeloid sarcoma. , 2020, , .		0
201	Abstract 4833: Unraveling the role of microRNAs in multiple primary melanoma pathogenesis. , 2020, , .		0
202	Sickle Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report. American Journal of Case Reports, 2022, 23, e934220.	0.8	0
203	Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma. , 2022, , 339-384.		0
204	Dysplastic nevi and melanoma: microRNAs tell a divergent story. Pathology Research and Practice, 2022, , 153942.	2.3	0